J Dawn Waters

Summary

Publications

  1. ncbi CT322, a VEGFR-2 antagonist, demonstrates anti-glioma efficacy in orthotopic brain tumor model as a single agent or in combination with temozolomide and radiation therapy
    J Dawn Waters
    Division of Neurosurgery, University of California San Diego, La Jolla, CA 92093, USA
    J Neurooncol 110:37-48. 2012
  2. ncbi Malignancies of the spinal cord
    J Dawn Waters
    Division of Neurosurgery, University of California San Diego Medical Center San Diego, California, USA
    Adv Exp Med Biol 760:101-13. 2012

Detail Information

Publications2

  1. ncbi CT322, a VEGFR-2 antagonist, demonstrates anti-glioma efficacy in orthotopic brain tumor model as a single agent or in combination with temozolomide and radiation therapy
    J Dawn Waters
    Division of Neurosurgery, University of California San Diego, La Jolla, CA 92093, USA
    J Neurooncol 110:37-48. 2012
    ..These pre-clinical results provide the foundation to further understand long term response and tumor escape mechanisms to anti-angiogenic treatments on EGFR over-expressing glioblastomas...
  2. ncbi Malignancies of the spinal cord
    J Dawn Waters
    Division of Neurosurgery, University of California San Diego Medical Center San Diego, California, USA
    Adv Exp Med Biol 760:101-13. 2012
    ..This section will review the pathophysiology and epidemiology of IMSCT and the state-of-the-art management before delving into the promising new tools and techniques for each phase of management...